Literature DB >> 6219615

Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans.

J Shimada, T Yamaji, Y Ueda, H Uchida, H Kusajima, T Irikura.   

Abstract

The mechanisms of the renal excretion of AM-715, a synthetic antimicrobial agent, were studied in rabbits, dogs, and humans. In both rabbits and humans, AM-715 clearance was greater than creatinine clearance and was profoundly decreased by the administration of probenecid. Thus, in these subjects, AM 715 was cleared by both tubular secretion and glomerular filtration. In dogs, however, the excretion ratio (close to unity), biological half-life, and stop-flow pattern of AM-715 were not affected by probenecid, indicating that the renal excretion of AM-715 took place mostly through glomerular filtration. These results suggest that renal excretion of AM-715 differs with animal species.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6219615      PMCID: PMC184605          DOI: 10.1128/AAC.23.1.1

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  A new spectrophotometric method for the detection and determination of keto sugars and trioses.

Authors:  Z DISCHE; E BORENFREUND
Journal:  J Biol Chem       Date:  1951-10       Impact factor: 5.157

2.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of probenecid.

Authors:  R F Cunningham; Z H Israili; P G Dayton
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

4.  Cinoxacin: pharmacokinetics and the effect of probenecid.

Authors:  K S Israel; H R Black; R L Nelson; M K Brunson; J F Nash; G L Brier; J D Wolney
Journal:  J Clin Pharmacol       Date:  1978-10       Impact factor: 3.126

5.  Renal effects of bumetanide.

Authors:  T Higashio; Y Abe; K Yamamoto
Journal:  J Pharmacol Exp Ther       Date:  1978-10       Impact factor: 4.030

6.  Influence of probenecid on serum levels and urinary excretion of cinoxacin.

Authors:  N Rodriguez; P O Madsen; P G Welling
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

7.  Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections.

Authors:  K Hirai; A Ito; Y Abe; S Suzue; T Irikura; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

  7 in total
  25 in total

1.  Norfloxacin blood-brain barrier transport in rats is not affected by probenecid coadministration.

Authors:  Sandrine Marchand; Anna Forsell; Marylore Chenel; Emmanuelle Comets; Isabelle Lamarche; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Renal handling of fleroxacin in rabbits, dogs, and humans.

Authors:  K Shiba; A Saito; J Shimada; S Hori; M Kaji; T Miyahara; H Kusajima; S Kaneko; S Saito; T Ooie
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

3.  Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig; Jürgen B Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

4.  Possible role of metabolite in flosequinan-related mortality.

Authors:  F Kamali; C Edwards
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

5.  Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process.

Authors:  L Rabbaa; S Dautrey; N Colas-Linhart; C Carbon; R Farinotti
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 6.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

7.  The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin.

Authors:  R Wise; D Lister; C A McNulty; D Griggs; J M Andrews
Journal:  Infection       Date:  1986       Impact factor: 3.553

Review 8.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

9.  Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin.

Authors:  Adam L Vanwert; Chutima Srimaroeng; Douglas H Sweet
Journal:  Mol Pharmacol       Date:  2008-04-01       Impact factor: 4.436

Review 10.  Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; R N Brogden; D M Richards
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.